The purpose of this study is to evaluate time to progression (TTP) by PSA in patients with high risk prostate cancer after definitive therapy.

Inclusion Criteria:

• Patients who have undergone a radical prostatectomy (should have unmeasurable PSA) or radiation therapy for prostate cancer and who have high risk disease as defined by one of the following:

  • Node positive disease post-operatively

  • Capsule involvement

  • Seminal Vesicles involvement

  • Gleason score ≥ 8

  • >50% of core biopsies that are positive

  • Clinical Stage T2c and T3

  • Pre-op PSA > 15 plus Gleason score of 7

    • Age greater than 18
    • ECOG Performance Status 0-1
    • Serum creatinine <= 1.5 mg/dl
    • Granulocyte count >= 1500/m3, Hemoglobin > 8.0 g/dl, and platelet count >= 100,000/m3
    • Total bilirubin <= ULN
    • AST, ALT and Alkaline Phosphatase must be within the range allowing for eligibility.
    • Signed patient informed consent.
    • Men of childbearing potential must be willing to consent to using effective contraception while on treatment and for three months thereafter.

Exclusion Criteria:

• Peripheral neuropathy > grade 1
• History of severe hypersensitivity to Taxotere® or other drugs formulated with polysorbate 80.
• Patients who have received previous chemotherapy or are being treated on another clinical trial using an investigational agent.
• Active infection within 14 days of beginning treatment
• Patients with a serious illness or medical condition, history of significant neurologic or psychiatric or active infection.
• Patients with a current malignancy. Patients with prior a history of in situ lobular carcinoma of the breast, basal or squamous cell skin cancer, are eligible.